FDA extends digoxin elixir NDA deadline
Executive Summary
FDA extends deadline for companies to have an approved application for digoxin elixir from June 28 to Dec. 28. The extension was made because "it now appears that...there may not be any manufacturers prepared to market digoxin elixir under an approved application," a 1notice published in the June 29 Federal Register states. FDA set the original deadline in a final rule published June 28, 2002, which also required NDAs for digoxin tablets (2"The Pink Sheet" July 1, 2002, p. 12)...
You may also be interested in...
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.